Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery, lower cost, and an opportunity for earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's initial lead product candidates, PTG-100 and PTG-200, are based on this approach, and the company believes they have the potential to transform the existing treatment paradigm for IBD, a GI disease consisting primarily of ulcerative colitis and Crohn's disease.
Founder: Mark Symythe
CEO: Dinesh Patel
CMO (Marketing): Richard Shames
CFO: Tom O’Neil
CSO (Scientific): David Liu
Please click here for Protagonist Therapeutics job opportunities.
Please click here for clinical trial information.
183 articles with Protagonist Therapeutics, Inc.
Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia Vera
Protagonist Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its lead investigational new drug candidate, rusfertide, for the treatment of patients with polycythemia vera (PV)
Shares of Protagonist Therapeutics climbed nearly 4% in premarket trading after the company announced its lead drug candidate rusfertide snagged Breakthrough Therapy Designation from the U.S. FDA.
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232
Protagonist Therapeutics, Inc. announced that the first human subject has been dosed in a Phase 1 study of PN-232, a novel oral interleukin-23 receptor antagonist peptide.
Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021
Protagonist Therapeutics ("Protagonist" or the "Company") (Nasdaq: PTGX), today announced that an abstract highlighting updated data from its ongoing Phase 2 clinical study evaluating rusfertide irusfertide in polycythemia vera ("PV") has been selected for an oral presentation at the upcoming European Hematology Association ("EHA") 2021 Annual Congress.
Protagonist Therapeutics reported financial results for the first quarter of 2021 ended March 31, 2021 and provided a corporate update.
Protagonist Therapeutics, Inc. reported that on April 30, 2021, it issued an inducement award to Ramesh Bhatt, the Company's recently hired Vice President, Discovery Biology and Translational Research, in accordance with the terms of Dr. Bhatt's employment offer letter.
Protagonist Therapeutics Completes Enrollment for Phase 2 Study of Rusfertide in Polycythemia Vera and Announces Plans for Data Update at an Upcoming Medical Meeting
-- Rapid completion of Phase 2 enrollment signals further momentum for the development of rusfertide in polycythemia vera --
Protagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with the U.S. Food & Drug Administration and the European Medicines Agency
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") announced today that the Division of Nonmalignant Hematology at the U.S. Food and Drug Administration ("FDA") has provided important feedback during an End-of-Phase 2 meeting on rusfertide (PTG-300), an investigational new treatment for polycythemia vera ("PV")
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
Regulatory guidance anticipated in the first half of 2021 for registrational clinical development plan of investigational drug, rusfertide (PTG-300), for polycythemia vera
Protagonist Therapeutics, Inc. (Nasdaq: PTGX), today announced it will host a conference call and webcast on Wednesday, March 10 at 4:30 pm ET / 1:30 pm PT to discuss its fourth quarter and full year 2020 financial results. Conference Call and Webcast Information
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and will host one-on-one meetings with investors at the upcoming virtual H.C. Wainwright Global Life Sciences Conference taking place March 9 to March 10, 2021.
Protagonist Therapeutics, Inc. reported that on February 26, 2021, it issued an inducement award to Jami Taylor, the Company's recently hired Vice President, Corporate Affairs, in accordance with the terms of Ms.
Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at SVB Leerink Virtual 10th Annual Global Healthcare Conference taking place February 22 to February 26, 2021 .
Protagonist Therapeutics, Inc. reported that on January 29, 2021, it issued an inducement award to Paula O'Connor, M.D., the Company's recently hired Senior Vice President, Clinical Development, in accordance with the terms of Dr. O'Connor's employment offer letter.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 , at 2:00 p.m EST. A live and archived webcast of the event will be available in the Investors section o
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first subject has been dosed in a Phase 1 study of PN-235 (also referenced as JNJ-77242113), an oral interleukin-23 receptor (IL-23R) antagonist peptide.
Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 5,476,189 shares of its common stock
Protagonist Therapeutics, Inc., a clinical stage biopharmaceutical company, announced the pricing of its previously announced underwritten public offering of 4,761,904 shares of its common stock at a price to the public of $21.00 per share.
Protagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population Categories
Treatment options did not provide hematocrit control consistent with NCCN guidelines for up to 78 percent of patients as presented at the American Society for Hematology (ASH) 2020 annual meeting
Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
PTG-300 controlled hematocrit and reversed iron deficiency in patients receiving therapeutic phlebotomy, cytoreductive therapy or interferon